Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Has A First With Labetalol Launch In US

Also Introduces Hydralazine And Estradiol Valerate As Part Of Latest Injectables Push

Executive Summary

Hikma says it is breaking new ground in the US with a ready-to-use presentation of labetalol. Meanwhile, the company has also added hydralazine to its list of recent injectables launches.

You may also be interested in...



Hikma Has A Trio Of US Launches

Hikma has added three products – a generic version of Banzel tablets and injectables ganciclovir and doxycycline – to its US portfolio.

Advair Relaunch And Nasal Naloxone Nod Raise Hikma’s Expectations

Fresh from resuming launch of its generic version of Advair in the US, Hikma has also been boosted by an FDA approval for its 505(b)(2) naloxone 8mg nasal spray. Both developments are expected to drive the firm’s generics business to the top end of its guidance for 2021, management revealed.

Hyloris And Hikma Ally On Maxigesic IV In US

Hyloris has secured Hikma as its US marketing partner for Maxigesic IV. The deal gives Hyloris access to Hikma’s presence in complex, injectable hospital products while aligning with Hikma’s push into differentiated treatments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;